Summary of Alpha Cognition Fireside Chat - December 02, 2025 Company Overview - Company: Alpha Cognition (NasdaqCM: ACOG) - Product: ZUNVEYL, targeting the long-term care market for Alzheimer's patients - Market Size: Approximately $2.2 billion for long-term care related to Alzheimer's disease [5][6] Key Performance Metrics - Sales: Reported $2.3 million in sales for Q3 2025 [5] - Key Performance Indicators (KPIs): - Physician prescribing and repeat orders - Nursing home orders and repeat orders - Adherence rates between 5 mg and 10 mg doses - Payer metrics, including plans covered and lives covered without restriction [5] Market Penetration and Adoption - Target Market: Approximately 5,000 specialized nursing homes in the U.S. [6] - Current Adoption: - 600 nursing homes have written prescriptions; 550 homes wrote orders in Q3 [6] - 60% refill or reorder rate in homes contacted [6] - 576 healthcare providers (HCP) writers in Q3, approaching 700 since launch [6] - Payer Contracts: Currently one contract covering 15% of lives; a second contract anticipated soon [10] Product Utilization - Dosage Distribution: 50% of patients on 5 mg and 50% on 10 mg; expected to shift to 75% on 10 mg at steady state [11] - Pricing: Flat pricing of $820 WAC per month for all doses; gross-to-net expected to stabilize at $500 in three years [13][15] Stakeholder Engagement - Key Stakeholders: - Medical directors (primary customers) - Psychiatrists (treat behavioral symptoms) - Directors of nursing (first to observe symptoms) - Consultant pharmacists (make treatment recommendations) [20][21] - Messaging: Focus on lower GI incidents and no insomnia with ZUNVEYL compared to competitors [22][24] Clinical Development - Ongoing Trials: - Converge Trial: Retrospective analysis of ZUNVEYL in long-term care; results expected in Q3 2026 [42][45] - Beacon Trial: Real-world evidence study assessing cognition and behavior in 200 patients; completion expected by end of 2026 [49] - Resolve Trial: Phase four observational trial in outpatient settings; expected to provide label-enabling data [64][68] International Strategy - China Market: Approximately 10 million patients; submission accepted in July 2025, with potential approval by late 2026 [95][96] - Economic Model: Milestone payments and high single-digit royalties from Asian markets; no marketing costs for Alpha Cognition [98] Financial Guidance - Operating Profitability: Expected in 2027, excluding non-cash items like depreciation [101] - R&D Spending: Anticipated to be $50 million-$55 million in 2026, with a decrease expected in 2027 due to fewer ongoing clinical studies [105][108] Additional Insights - Sublingual Formulation: Development underway to address patient difficulties in swallowing; estimated market opportunity of $200 million [69][70] - Department of Defense Study: Completed a bomb blast study showing positive cognitive effects; potential for IND submission for cognitive impairment in mild traumatic brain injury [88][89] This summary encapsulates the key points discussed during the fireside chat, highlighting Alpha Cognition's market strategy, product performance, clinical development, and financial outlook.
Alpha Cognition (NasdaqCM:ACOG) Fireside Chat Transcript